{"nctId":"NCT01729754","briefTitle":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","startDateStruct":{"date":"2013-02-05","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":1090,"armGroups":[{"label":"Tildrakizumab 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tildrakizumab 200 mg","Drug: Etanercept Placebo"]},{"label":"Tildrakizumab 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tildrakizumab 100 mg","Drug: Etanercept Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Tildrakizumab Placebo","Drug: Etanercept Placebo"]},{"label":"Etanercept 50 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tildrakizumab Placebo","Drug: Etanercept 50 mg"]}],"interventions":[{"name":"Tildrakizumab 200 mg","otherNames":["SCH 900222, MK-3222"]},{"name":"Tildrakizumab 100 mg","otherNames":["SCH 900222, MK-3222"]},{"name":"Tildrakizumab Placebo","otherNames":[]},{"name":"Etanercept Placebo","otherNames":[]},{"name":"Etanercept 50 mg","otherNames":["Embrel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to enrollment;\n* Candidate for phototherapy or systemic therapy;\n* Premenopausal female participants must agree to abstain from heterosexual activity or use a medically approved method of contraception or use appropriate effective contraception as per local regulations or guidelines\n* For the extension study: must have completed Part 3 of the base study\n* For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study\n\nExclusion Criteria:\n\n* Non-plaque forms of psoriasis\n* Presence or history of severe psoriatic arthritis and is well-controlled on current treatment regimen\n* Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating\n* Participant is expected to require topical therapy, phototherapy, or systemic therapy during the trial\n* Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics\n* Previous use of entanercept, tildrakizumab (MK-3222), or other interleukin-23 (IL-23)/T- helper cell 17 (Th-17) pathway inhibitors including p40, p19, and IL-17 antagonists\n* Latex allergy or sensitivity\n* Active or untreated latent tuberculosis (TB)\n* For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or are breast feeding\n* For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities\n* For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.6","spread":null},{"groupId":"OG001","value":"61.2","spread":null},{"groupId":"OG002","value":"5.8","spread":null},{"groupId":"OG003","value":"48.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Part 1)","description":"The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"54.7","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"47.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12 (Part 1)","description":"An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"44.3","spread":null},{"groupId":"OG002","value":"55.1","spread":null},{"groupId":"OG003","value":"54.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 12 (Part 1)","description":"An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.3","spread":null},{"groupId":"OG003","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-75 Response at Week 28 (Part 2)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Primary analysis for this endpoint is for participants randomized to tildrakizumab 200 mg, tildrakizumab 100 mg, or etanercept in Part 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":null},{"groupId":"OG001","value":"73.5","spread":null},{"groupId":"OG002","value":"53.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-75 Response at Week 40 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"92.6","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"63.3","spread":null},{"groupId":"OG004","value":"66.7","spread":null},{"groupId":"OG005","value":"61.9","spread":null},{"groupId":"OG006","value":"82.1","spread":null},{"groupId":"OG007","value":"68.8","spread":null},{"groupId":"OG008","value":"57.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-75 Response at Week 52 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"94.2","spread":null},{"groupId":"OG002","value":"93.6","spread":null},{"groupId":"OG003","value":"66.7","spread":null},{"groupId":"OG004","value":"78.9","spread":null},{"groupId":"OG005","value":"68.4","spread":null},{"groupId":"OG006","value":"92.4","spread":null},{"groupId":"OG007","value":"85.7","spread":null},{"groupId":"OG008","value":"81.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 28 (Part 2)","description":"The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"64.6","spread":null},{"groupId":"OG002","value":"45.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 40 (Part 3)","description":"The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"79.2","spread":null},{"groupId":"OG002","value":"84.9","spread":null},{"groupId":"OG003","value":"57.6","spread":null},{"groupId":"OG004","value":"38.1","spread":null},{"groupId":"OG005","value":"57.1","spread":null},{"groupId":"OG006","value":"75.8","spread":null},{"groupId":"OG007","value":"62.5","spread":null},{"groupId":"OG008","value":"50.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 52 (Part 3)","description":"The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"77.7","spread":null},{"groupId":"OG002","value":"79.4","spread":null},{"groupId":"OG003","value":"50.8","spread":null},{"groupId":"OG004","value":"42.1","spread":null},{"groupId":"OG005","value":"57.9","spread":null},{"groupId":"OG006","value":"77.3","spread":null},{"groupId":"OG007","value":"55.6","spread":null},{"groupId":"OG008","value":"68.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-90 Response at Week 12 (Part 1)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":null},{"groupId":"OG001","value":"38.8","spread":null},{"groupId":"OG002","value":"1.3","spread":null},{"groupId":"OG003","value":"21.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-90 Response at Week 28 (Part 2)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"55.5","spread":null},{"groupId":"OG002","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-90 Response at Week 40 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"73.1","spread":null},{"groupId":"OG002","value":"78.8","spread":null},{"groupId":"OG003","value":"28.3","spread":null},{"groupId":"OG004","value":"23.8","spread":null},{"groupId":"OG005","value":"42.9","spread":null},{"groupId":"OG006","value":"64.2","spread":null},{"groupId":"OG007","value":"48.4","spread":null},{"groupId":"OG008","value":"24.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-90 Response at Week 52 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"68.3","spread":null},{"groupId":"OG002","value":"78.4","spread":null},{"groupId":"OG003","value":"31.7","spread":null},{"groupId":"OG004","value":"26.3","spread":null},{"groupId":"OG005","value":"42.1","spread":null},{"groupId":"OG006","value":"63.6","spread":null},{"groupId":"OG007","value":"47.6","spread":null},{"groupId":"OG008","value":"41.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-100 Response at Week 12 (Part 1)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-100 Response at Week 28 (Part 2)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-100 Response at Week 40 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"38.9","spread":null},{"groupId":"OG002","value":"33.5","spread":null},{"groupId":"OG003","value":"11.7","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"14.3","spread":null},{"groupId":"OG006","value":"29.9","spread":null},{"groupId":"OG007","value":"28.1","spread":null},{"groupId":"OG008","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a PASI-100 Response at Week 52 (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"35.3","spread":null},{"groupId":"OG003","value":"10.0","spread":null},{"groupId":"OG004","value":"5.3","spread":null},{"groupId":"OG005","value":"31.6","spread":null},{"groupId":"OG006","value":"39.4","spread":null},{"groupId":"OG007","value":"23.8","spread":null},{"groupId":"OG008","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Dermatology Life Quality Index (DLQI)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"7.03"},{"groupId":"OG001","value":"14.8","spread":"7.24"},{"groupId":"OG002","value":"13.7","spread":"6.98"},{"groupId":"OG003","value":"14.5","spread":"7.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the DLQI at Week 12 (Part 1)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":null},{"groupId":"OG001","value":"-10.2","spread":null},{"groupId":"OG002","value":"-2.0","spread":null},{"groupId":"OG003","value":"-8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the DLQI at Week 28 (Part 2)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":null},{"groupId":"OG001","value":"-11.2","spread":null},{"groupId":"OG002","value":"-9.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the DLQI at Week 40 (Part 3)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.6","spread":"6.61"},{"groupId":"OG001","value":"-12.0","spread":"7.11"},{"groupId":"OG002","value":"-13.2","spread":"6.92"},{"groupId":"OG003","value":"-9.7","spread":"5.62"},{"groupId":"OG004","value":"-9.0","spread":"7.76"},{"groupId":"OG005","value":"-9.8","spread":"7.25"},{"groupId":"OG006","value":"-10.4","spread":"6.66"},{"groupId":"OG007","value":"-10.1","spread":"6.08"},{"groupId":"OG008","value":"-10.8","spread":"6.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the DLQI at Week 52 (Part 3)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.3","spread":"6.16"},{"groupId":"OG001","value":"-11.5","spread":"7.26"},{"groupId":"OG002","value":"-13.1","spread":"6.80"},{"groupId":"OG003","value":"-9.2","spread":"6.18"},{"groupId":"OG004","value":"-9.4","spread":"8.47"},{"groupId":"OG005","value":"-9.3","spread":"7.22"},{"groupId":"OG006","value":"-11.1","spread":"6.45"},{"groupId":"OG007","value":"-10.4","spread":"6.38"},{"groupId":"OG008","value":"-11.5","spread":"6.97"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a DLQI Score of 0 or 1 at Week 12 (Part 1)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"40.2","spread":null},{"groupId":"OG002","value":"8.0","spread":null},{"groupId":"OG003","value":"35.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a DLQI Score of 0 or 1 at Week 28 (Part 2)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null},{"groupId":"OG001","value":"54.1","spread":null},{"groupId":"OG002","value":"39.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a DLQI Score of 0 or 1 at Week 40 (Part 3)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"68.5","spread":null},{"groupId":"OG002","value":"71.2","spread":null},{"groupId":"OG003","value":"41.7","spread":null},{"groupId":"OG004","value":"9.5","spread":null},{"groupId":"OG005","value":"19.0","spread":null},{"groupId":"OG006","value":"50.7","spread":null},{"groupId":"OG007","value":"51.5","spread":null},{"groupId":"OG008","value":"38.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a DLQI Score of 0 or 1 at Week 52 (Part 3)","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"71.4","spread":null},{"groupId":"OG002","value":"68.8","spread":null},{"groupId":"OG003","value":"40.0","spread":null},{"groupId":"OG004","value":"10.5","spread":null},{"groupId":"OG005","value":"42.1","spread":null},{"groupId":"OG006","value":"60.0","spread":null},{"groupId":"OG007","value":"57.8","spread":null},{"groupId":"OG008","value":"48.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in PASI Score Over Time (Part 1)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"6.54"},{"groupId":"OG001","value":"-7.9","spread":"6.83"},{"groupId":"OG002","value":"-2.3","spread":"6.18"},{"groupId":"OG003","value":"-7.0","spread":"7.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":"7.71"},{"groupId":"OG001","value":"-12.8","spread":"7.57"},{"groupId":"OG002","value":"-3.1","spread":"7.18"},{"groupId":"OG003","value":"-11.4","spread":"8.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.4","spread":"7.77"},{"groupId":"OG001","value":"-15.1","spread":"7.94"},{"groupId":"OG002","value":"-3.4","spread":"6.77"},{"groupId":"OG003","value":"-13.5","spread":"8.29"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in PASI Score Over Time (Part 2)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"7.70"},{"groupId":"OG001","value":"-15.9","spread":"7.87"},{"groupId":"OG002","value":"-14.2","spread":"8.20"},{"groupId":"OG003","value":"-11.6","spread":"6.97"},{"groupId":"OG004","value":"-9.6","spread":"6.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":"7.66"},{"groupId":"OG001","value":"-16.7","spread":"7.88"},{"groupId":"OG002","value":"-14.5","spread":"8.32"},{"groupId":"OG003","value":"-15.1","spread":"6.55"},{"groupId":"OG004","value":"-13.7","spread":"7.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.0","spread":"7.81"},{"groupId":"OG001","value":"-16.5","spread":"7.71"},{"groupId":"OG002","value":"-14.8","spread":"7.85"},{"groupId":"OG003","value":"-17.3","spread":"7.62"},{"groupId":"OG004","value":"-14.5","spread":"8.46"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in PASI Score Over Time (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"7.13"},{"groupId":"OG001","value":"-19.0","spread":"8.03"},{"groupId":"OG002","value":"-18.7","spread":"6.83"},{"groupId":"OG003","value":"-14.0","spread":"5.72"},{"groupId":"OG004","value":"-15.0","spread":"6.69"},{"groupId":"OG005","value":"-15.5","spread":"7.08"},{"groupId":"OG006","value":"-16.9","spread":"7.68"},{"groupId":"OG007","value":"-16.4","spread":"8.02"},{"groupId":"OG008","value":"-10.5","spread":"6.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":"7.11"},{"groupId":"OG001","value":"-19.0","spread":"8.17"},{"groupId":"OG002","value":"-18.9","spread":"7.18"},{"groupId":"OG003","value":"-14.5","spread":"5.92"},{"groupId":"OG004","value":"-15.7","spread":"8.09"},{"groupId":"OG005","value":"-16.0","spread":"8.13"},{"groupId":"OG006","value":"-17.6","spread":"6.80"},{"groupId":"OG007","value":"-16.7","spread":"8.19"},{"groupId":"OG008","value":"-12.9","spread":"6.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.8","spread":"7.04"},{"groupId":"OG001","value":"-18.5","spread":"7.56"},{"groupId":"OG002","value":"-18.7","spread":"6.95"},{"groupId":"OG003","value":"-14.4","spread":"6.00"},{"groupId":"OG004","value":"-16.0","spread":"8.73"},{"groupId":"OG005","value":"-16.5","spread":"8.59"},{"groupId":"OG006","value":"-17.9","spread":"7.03"},{"groupId":"OG007","value":"-16.9","spread":"7.99"},{"groupId":"OG008","value":"-14.6","spread":"6.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"7.13"},{"groupId":"OG001","value":"-18.1","spread":"7.45"},{"groupId":"OG002","value":"-18.7","spread":"6.76"},{"groupId":"OG003","value":"-14.5","spread":"5.99"},{"groupId":"OG004","value":"-16.2","spread":"8.76"},{"groupId":"OG005","value":"-15.8","spread":"9.72"},{"groupId":"OG006","value":"-17.9","spread":"6.24"},{"groupId":"OG007","value":"-17.1","spread":"7.30"},{"groupId":"OG008","value":"-15.6","spread":"7.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":"7.13"},{"groupId":"OG001","value":"-18.4","spread":"7.66"},{"groupId":"OG002","value":"-18.4","spread":"6.65"},{"groupId":"OG003","value":"-14.6","spread":"5.72"},{"groupId":"OG004","value":"-15.5","spread":"9.00"},{"groupId":"OG005","value":"-16.3","spread":"9.55"},{"groupId":"OG006","value":"-18.1","spread":"7.00"},{"groupId":"OG007","value":"-17.0","spread":"7.30"},{"groupId":"OG008","value":"-16.2","spread":"6.83"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in PASI Score Over Time (Part 1)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.2","spread":"27.86"},{"groupId":"OG001","value":"-39.3","spread":"30.02"},{"groupId":"OG002","value":"-11.7","spread":"30.37"},{"groupId":"OG003","value":"-33.9","spread":"33.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.7","spread":"26.58"},{"groupId":"OG001","value":"-63.8","spread":"29.65"},{"groupId":"OG002","value":"-15.3","spread":"35.95"},{"groupId":"OG003","value":"-55.7","spread":"35.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.0","spread":"22.31"},{"groupId":"OG001","value":"-74.8","spread":"28.11"},{"groupId":"OG002","value":"-17.4","spread":"32.95"},{"groupId":"OG003","value":"-66.7","spread":"30.78"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in PASI Score Over Time (Part 2)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.0","spread":"21.26"},{"groupId":"OG001","value":"-79.3","spread":"25.27"},{"groupId":"OG002","value":"-70.3","spread":"27.55"},{"groupId":"OG003","value":"-59.2","spread":"28.34"},{"groupId":"OG004","value":"-49.4","spread":"28.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.6","spread":"17.58"},{"groupId":"OG001","value":"-82.9","spread":"23.16"},{"groupId":"OG002","value":"-71.9","spread":"29.40"},{"groupId":"OG003","value":"-77.9","spread":"20.25"},{"groupId":"OG004","value":"-70.1","spread":"25.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-85.7","spread":"17.44"},{"groupId":"OG001","value":"-82.5","spread":"22.33"},{"groupId":"OG002","value":"-73.5","spread":"24.40"},{"groupId":"OG003","value":"-84.0","spread":"16.89"},{"groupId":"OG004","value":"-72.9","spread":"30.05"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in PASI Score Over Time (Part 3)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and \\<75% improvement in PASI response from baseline at Week 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.9","spread":"6.19"},{"groupId":"OG001","value":"-94.0","spread":"7.02"},{"groupId":"OG002","value":"-94.3","spread":"7.33"},{"groupId":"OG003","value":"-77.1","spread":"16.73"},{"groupId":"OG004","value":"-71.1","spread":"13.21"},{"groupId":"OG005","value":"-75.3","spread":"16.90"},{"groupId":"OG006","value":"-84.4","spread":"24.18"},{"groupId":"OG007","value":"-81.6","spread":"21.69"},{"groupId":"OG008","value":"-54.7","spread":"24.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.5","spread":"7.47"},{"groupId":"OG001","value":"-94.0","spread":"6.93"},{"groupId":"OG002","value":"-94.4","spread":"7.06"},{"groupId":"OG003","value":"-79.9","spread":"15.94"},{"groupId":"OG004","value":"-74.4","spread":"15.69"},{"groupId":"OG005","value":"-77.9","spread":"15.47"},{"groupId":"OG006","value":"-87.7","spread":"15.20"},{"groupId":"OG007","value":"-83.1","spread":"19.83"},{"groupId":"OG008","value":"-65.9","spread":"21.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.2","spread":"7.69"},{"groupId":"OG001","value":"-92.6","spread":"10.25"},{"groupId":"OG002","value":"-94.3","spread":"7.40"},{"groupId":"OG003","value":"-79.1","spread":"17.10"},{"groupId":"OG004","value":"-75.7","spread":"19.24"},{"groupId":"OG005","value":"-80.6","spread":"17.57"},{"groupId":"OG006","value":"-88.2","spread":"14.55"},{"groupId":"OG007","value":"-84.1","spread":"17.08"},{"groupId":"OG008","value":"-76.5","spread":"17.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.8","spread":"7.77"},{"groupId":"OG001","value":"-91.4","spread":"12.09"},{"groupId":"OG002","value":"-94.3","spread":"7.64"},{"groupId":"OG003","value":"-79.3","spread":"17.77"},{"groupId":"OG004","value":"-77.1","spread":"19.67"},{"groupId":"OG005","value":"-75.3","spread":"23.35"},{"groupId":"OG006","value":"-90.3","spread":"12.32"},{"groupId":"OG007","value":"-86.9","spread":"13.08"},{"groupId":"OG008","value":"-80.3","spread":"17.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.7","spread":"8.06"},{"groupId":"OG001","value":"-92.2","spread":"10.57"},{"groupId":"OG002","value":"-93.4","spread":"9.81"},{"groupId":"OG003","value":"-80.4","spread":"15.68"},{"groupId":"OG004","value":"-75.7","spread":"36.00"},{"groupId":"OG005","value":"-79.6","spread":"21.46"},{"groupId":"OG006","value":"-91.0","spread":"12.16"},{"groupId":"OG007","value":"-87.1","spread":"12.90"},{"groupId":"OG008","value":"-84.2","spread":"16.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":527},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Arthralgia","Injection site erythema"]}}}